CMS Obtained Exclusive License of a Regenerative Medical Aesthetic Product
- The Group’s dermatology and medical aesthetics business, “CMS Skinhealth”, obtained an exclusive license to commercialize the Poly-L-lactic Acid Microparticle Filler Injection in Mainland China, HK, Macao and Taiwan
- PLLA, the main component of the Product, gradually degrades after injection, and effectively stimulates human body’s collagen regeneration to promote skin rejuvenation. The Product adopts patented microparticle preparation process, which turns microparticles into regular shape and uniform size. Microparticles can be evenly distributed beneath the dermis, and the product could achieve relatively sound performance in the clinical application.
- The Product fills the blank of regenerative medical aesthetic product of CMS Skinhealth, and will synergize with existing mainstream light medical aesthetic products such as the marketed Korean hyaluronic acid product, Vmonalisa, and the pipeline product BMI Botulinum Toxin etc., developing a comprehensive medical aesthetic solution
On May 30, the subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) – a dermatology and medical aesthetic company “CMS Skinhealth” entered into an exclusive license agreement with Jiangsu Xihong Biopharma Co., Ltd.(“Xihong Biopharma”) for Poly-L-lactic Acid Microparticle Filler Injection (the “Product”). In accordance with the license agreement, CMS Skinhealth obtained an exclusive license to promote, market and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan. The exclusive license period shall begin from the date of the approval of the registration certificate of class III medical device of the Product in Mainland China and shall last until the tenth anniversary of the aforementioned date of approval. Upon the expiration of the aforementioned term, the license period may automatically be extended for another period of ten years thereafter if it complies with the exclusive license agreement.
Poly-L-lactic Acid Microparticle Filler Injection, is developed for deep dermis and subcutaneous layer to correct moderate to severe nasolabial fold wrinkles. The product is a class III medical device, and it is in the clinical trial stage for registration in China.
Mr. Huang Anjun, the general manager of CMS Skinhealth, stated that the Product fills the blank of regenerative medical aesthetic product of CMS Skinhealth, enriching the light medical aesthetic product portfolio and further enhancing the comprehensive competitiveness of CMS Skinhealth in medical aesthetic field. In the meantime, the Product will synergize with existing mainstream light medical aesthetic products such as the marketed Korean hyaluronic acid product, Vmonalisa, and the pipeline product BMI Botulinum Toxin etc., developing a comprehensive medical aesthetic solution to meet the diversified and customized needs of consumers.
Poly-L-lactic Acid (PLLA), the main component of the Product, is the high polymer material that is highly biocompatible and completely degradable, and is widely used in the fields of medical aesthetics, sports medicine, neurosurgery, etc., with proven safety and efficacy. PLLA gradually degrades after injection, which can effectively stimulate human body’s collagen regeneration to promote skin rejuvenation. In addition, the Product adopts patented microparticle preparation process, which turns microparticles into regular shape and uniform size, and microparticles can be evenly distributed beneath the dermis, and the product could achieve relatively sound performance in the clinical application.
According to data from So Young Institute (新氧数据颜究院), among the online transaction of medical aesthetic products in 2022, the proportion of non-surgical orders is higher than that of surgical orders, accounting for 84% overall orders, with an increase of 5 percentage point compared to 2021. As an emerging non-surgical light medical aesthetic category, regenerative medical aesthetic product brings structural innovation in aesthetics, technology and treatment protocols, and it has gradually entered into a standardized growth and development cycle. Meanwhile, the growing anti-aging demands are expected to boost the development and penetration of the regenerative product. By leveraging the resources and channels of CMS Skinhealth in the dermatology and medical aesthetics field, the Product is expected to seize the rapid development opportunities of the regenerative medical aesthetics materials.
About Xihong Biopharma
Founded in 2016, Xihong Biopharma, is a healthcare company focusing on research and development, production and sales of Class III medical aesthetic devices and formula food for special medical use. The core technologies of the company can support the microparticle preparation of various medical aesthetic materials, realizing multiple gel modification and developing a products portfolio with short-, medium- and long-validation period. Please refer to the company’s official website for details: https://en.jsxihong.com/
About CMS Skinhealth:
The Group’s Dermatology and Medical Aesthetic Business adheres to an operation philosophy of “using medical thinking to promote in-depth study of dermatology and aesthetics”, and it adopts the scientific mindset to build the dermatology and medical aesthetic product matrix with dermatology prescription products as the core, achieving full life-cycle skin-health management covering dermatological treatment, skincare and medical aesthetics. As of 31 December 2022, team size of CMS Skinhealth exceeded 600 people, covering nearly 10,000 hospitals and medical institutions in China.